Thomas Abrams, MD: Overall Survival Data From the HIMALAYA Trial
Dr. Abrams explains overall survival (OS) data from the HIMALAYA trial, including updated 5-year OS data. This trial showed that the STRIDE regimen (durvalumab + tremelimumab) led to improved OS in patients with unresectable hepatocellular carcinoma, compared to sorafenib monotherapy. Additionally, Dr. Abrams shares how he utilizes the STRIDE regimen in his clinical practice.
Topics covered:
- OS benefit with STRIDE regimen vs sorafenib
- 5-year post-hoc OS data from the HIMALAYA clinical trial
- Applying the STRIDE regimen to clinical practice
